PolyNovo Limited Stock

Equities

PNV

AU000000PNV0

Medical Equipment, Supplies & Distribution

Market Closed - Australian S.E. 02:10:53 2024-05-31 am EDT 5-day change 1st Jan Change
2.25 AUD +2.27% Intraday chart for PolyNovo Limited +8.17% +35.95%
Sales 2024 * 103M 68.3M Sales 2025 * 133M 88.68M Capitalization 1.55B 1.03B
Net income 2024 * 3M 2M Net income 2025 * 13M 8.65M EV / Sales 2024 * 14.7 x
Net cash position 2024 * 42.64M 28.36M Net cash position 2025 * 37.06M 24.65M EV / Sales 2025 * 11.4 x
P/E ratio 2024 *
373 x
P/E ratio 2025 *
115 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 88.66%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.27%
1 week+8.17%
1 month+9.76%
3 months-1.32%
6 months+63.64%
Current year+35.95%
More quotes
1 week
2.08
Extreme 2.08
2.25
1 month
2.01
Extreme 2.005
2.32
Current year
1.48
Extreme 1.475
2.52
1 year
1.10
Extreme 1.095
2.52
3 years
0.84
Extreme 0.835
2.92
5 years
0.84
Extreme 0.835
4.08
10 years
0.07
Extreme 0.07
4.08
More quotes
Managers TitleAgeSince
Chief Executive Officer - 22-07-28
Director of Finance/CFO - 18-12-11
Chief Tech/Sci/R&D Officer - 23-05-21
Members of the board TitleAgeSince
Chairman 70 14-02-27
Director/Board Member 68 10-02-17
Chief Tech/Sci/R&D Officer - 12-08-05
More insiders
Date Price Change Volume
24-05-31 2.25 +2.27% 1,865,960
24-05-30 2.2 +2.33% 1,393,522
24-05-29 2.15 +1.42% 1,705,980
24-05-28 2.12 +0.47% 1,159,628
24-05-27 2.11 +1.44% 727,122

Delayed Quote Australian S.E., May 31, 2024 at 02:10 am EDT

More quotes
PolyNovo Limited is an Australia-based medical device company, which is focused on advanced wound care that designs, develops, and manufactures dermal regeneration solutions using its patented NovoSorb biodegradable polymer technology. Its solutions include NovoSorb Biodegradable Temporizing Matrix (BTM) and NovoSorb MTX. NovoSorb BTM is a synthetic, biodegradable and biocompatible device designed to facilitate the dermis to grow within a patented polyurethane matrix when lost through extensive surgery, trauma or burn. NovoSorb BTM is indicated for use in the management of wounds, including partial and full thickness wounds, pressure ulcers, venous and diabetic ulcers, chronic and vascular ulcers, surgical wounds, trauma wounds and draining wounds. Its development program covers breast sling, hernia, and orthopedic applications. NovoSorb MTX is available in a range of sizes to address acute and chronic dermal wounds and is comprised of a 2mm biodegradable foam with no sealing membrane.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
2.25 AUD
Average target price
2.113 AUD
Spread / Average Target
-6.07%
Consensus